BMRN logo

BioMarin Pharmaceutical Inc.

BMRN
Healthcare|Biotechnology|US
$56.03
-0.09 (-0.16%)
DCF Value
$7.43
Tangible Book / Share
$4.20
Cash / Share
$3.80

Analyst Consensus

Buy41 analysts
Strong Buy
0
Buy
29
Hold
12
Sell
0
Strong Sell
0
Consensus Target
$89.13
Implied Upside
+59.1%
Low Target
$59.00
High Target
$122.00

Price Target Trend

Last Month
$99.00
4 targets · +77% vs price
Last Quarter
$96.07
15 targets · +71% vs price
Last Year
$91.54
39 targets · +63% vs price
All Time
$95.10
86 targets · +70% vs price

Rating Trend

Dec 25
21 buy · 7 hold · 0 sell
Jan 26
18 buy · 7 hold · 0 sell
Feb 26
18 buy · 6 hold · 0 sell
Mar 26
18 buy · 5 hold · 0 sell
Apr 26
19 buy · 5 hold · 0 sell
May 26
21 buy · 6 hold · 0 sell
Jun 26
20 buy · 6 hold · 0 sell
Jul 26
20 buy · 6 hold · 0 sell
Aug 26
20 buy · 7 hold · 0 sell
Sep 26
20 buy · 7 hold · 0 sell
Oct 26
22 buy · 7 hold · 0 sell
Nov 26
21 buy · 7 hold · 0 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 3, 2026OppenheimerLeland Gershell$94.00(+64%)$57.44StreetInsider
Nov 3, 2026Stifel NicolausPaul Matteis$66.00(+15%)$57.44StreetInsider
Oct 21, 2026Morgan Stanley$122.00(+116%)$56.48TheFly
Oct 14, 2026Barclays$114.00(+110%)$54.38TheFly
Sep 15, 2026BMO Capital$97.00(+50%)$64.60TheFly
Sep 1, 2026Cantor Fitzgerald$86.00(+32%)$65.31TheFly
Sep 1, 2026Piper Sandler$90.00(+38%)$65.23TheFly
Aug 31, 2026JefferiesAkash Tewari$105.00(+60%)$65.53TheFly
Aug 31, 2026Raymond James$109.00(+67%)$65.39TheFly
Aug 26, 2026UBS$88.00(+33%)$66.10StreetInsider
Aug 18, 2026BMO CapitalDavid Lebowitz$98.00(+46%)$66.99TheFly
Aug 18, 2026H.C. Wainwright$59.00(-13%)$67.79TheFly
Aug 17, 2026Piper Sandler$88.00(+31%)$67.36TheFly
Aug 17, 2026BarclaysEliana Merle$111.00(+65%)$67.36TheFly
Aug 10, 2026Canaccord GenuityWhitney Ijem$114.00(+79%)$63.81StreetInsider
Aug 7, 2026Raymond James$105.00(+65%)$63.80TheFly
Aug 7, 2026Morgan Stanley$124.00(+94%)$63.84TheFly
Aug 7, 2026Stifel Nicolaus$70.00(+10%)$63.55TheFly
Aug 7, 2026OppenheimerLeland Gershell$97.00(+58%)$61.46StreetInsider
Jul 7, 2026RBC CapitalLuca Issi$62.00(+5%)$58.79TheFly

Recent Rating Actions

FirmActionRatingDate
JP MorganmaintainOverweightNov 4, 2026
StifelmaintainHoldNov 3, 2026
Morgan StanleymaintainOverweightNov 3, 2026
OppenheimermaintainOutperformNov 3, 2026
HC Wainwright & Co.maintainNeutralNov 3, 2026
RBC CapitalmaintainSector PerformNov 3, 2026
Morgan StanleymaintainOverweightOct 21, 2026
JP MorganmaintainOverweightOct 20, 2026
Cantor FitzgeraldmaintainOverweightOct 20, 2026
BarclaysmaintainOverweightOct 14, 2026
HC Wainwright & Co.maintainNeutralSep 10, 2026
Piper SandlermaintainOverweightSep 1, 2026
HC Wainwright & Co.maintainNeutralAug 31, 2026
JefferiesmaintainBuyAug 31, 2026
BMO CapitalmaintainOutperformAug 19, 2026
HC Wainwright & Co.maintainNeutralAug 18, 2026
BarclaysmaintainOverweightAug 17, 2026
Piper SandlermaintainOverweightAug 17, 2026
Canaccord GenuitymaintainBuyAug 10, 2026
HC Wainwright & Co.maintainNeutralAug 7, 2026
Morgan StanleymaintainOverweightAug 7, 2026
OppenheimermaintainOutperformAug 7, 2026
CitigroupmaintainBuyJul 16, 2026
RBC CapitalmaintainSector PerformJul 7, 2026
Canaccord GenuitymaintainBuyMay 22, 2026

Earnings History

Next report: Feb 22, 2027 · EPS est. $0.82
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Nov 2, 2026$0.23$-0.05$1.02B$1.02B
Aug 6, 2026$1.20$0.95$989.7M$932.0M
May 4, 2026$0.76$0.78$766.0M$752.5M
Feb 23, 2026$-0.24$0.17$874.6M$833.7M
Oct 27, 2025$-0.16$-0.15$776.1M$777.5M
Aug 4, 2025$1.23$0.86$825.0M$761.9M
May 1, 2025$0.97$0.71$745.1M$738.7M
Feb 19, 2025$0.64$0.54$747.0M$712.3M

News

Bfsg LLC Buys 17,538 Shares of BioMarin Pharmaceutical Inc. $BMRN

Bfsg LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 17,538 shares of the biotechnology company's stock, valued at approximately $1,052,000. Other hedge funds and other institutional investors also recently added to

Nov 6, 2026defenseworld.net
Traders Buy Large Volume of BioMarin Pharmaceutical Call Options (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders acquired 3,961 call options on the stock. This is an increase of approximately 228% compared to the typical daily volume of 1,206 call options. BioMarin Pharmaceutical News Summary Here are the key news stories impacting

Nov 5, 2026defenseworld.net
BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions

BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, and a full approval would further strengthen BMRN's existing achondroplasia franchise. Their Amicus acquisition also brings new revenue sources, though I reckon it remains to be seen if it fully justifies the debt required to finance the transaction.

Nov 4, 2026seekingalpha.com
BioMarin to Participate in Upcoming Investor Conferences

Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.

Nov 4, 2026prnewswire.com
BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript

BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Brian Mueller - CFO & Executive VP of Finance Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Eliana Merle - Barclays Bank PLC, Research Division Adit…

Nov 3, 2026seekingalpha.com
BioMarin Pharmaceutical Q3 Earnings Call Highlights

BioMarin Pharmaceutical NASDAQ: BMRN reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic conditions business grew 44%.

Nov 2, 2026marketbeat.com
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Nov 2, 2026zacks.com
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $0.12 per share a year ago.

Nov 2, 2026zacks.com
BioMarin Reports Third Quarter 2026 Financial and Operating Results

Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (H…

Nov 2, 2026prnewswire.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $58.44 and traded as high as $59.37. BioMarin Pharmaceutical shares last traded at $58.51, with a volume of 2,273,689 shares. Analyst Ratings Changes Several equities research analysts

Oct 31, 2026defenseworld.net
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease

Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease BioMarin will make an upfront payment of $70 million; GC and Hanmi will be jointly eligible to receive additional payments upon certain development and commercial milestones, and tiered royalties on net sales of HM15421/GC1134A SAN RAFAEL, Calif., Oct. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today an…

Oct 29, 2026prnewswire.com
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET

SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m.

Oct 26, 2026prnewswire.com
Quadrant Capital Group LLC Makes New $564,000 Investment in BioMarin Pharmaceutical Inc. $BMRN

Quadrant Capital Group LLC bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) during the undefined quarter, according to its most recent filing with the SEC. The fund bought 9,402 shares of the biotechnology company's stock, valued at approximately $564,000. Several other institutional investors have also made changes to their

Oct 26, 2026defenseworld.net
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oct 19, 2026zacks.com
BioMarin Pharmaceutical Inc. $BMRN Stock: Assenagon Asset Management S.A. Lowers Position

Assenagon Asset Management S.A. trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,339,560 shares of the biotechnology company's stock after selling 422,526 shares during

Oct 17, 2026defenseworld.net
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Oct 13, 2026zacks.com
Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)

Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk. Analyst Recommendations This is a summary of recent

Oct 12, 2026defenseworld.net
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypoch…

Oct 9, 2026prnewswire.com
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

Oct 7, 2026zacks.com
BioMarin Appoints Cara Bauer as Chief People Officer

Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D.

Oct 5, 2026prnewswire.com